UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/597,719	04/30/2007	Sheetal Mansukhlal Shah	70397	5346	
	yngenta Crop Protection, Inc.,			EXAMINER	
Patent and Trademark Department 410 Swing Road Greensboro, NC 27409			HIRIYANNA, KELAGINAMANE T		
			ART UNIT	PAPER NUMBER	
			1633		
			MAIL DATE	DELIVERY MODE	
			04/27/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/597,719	SHAH ET AL.
Office Action Summary	Examiner	Art Unit
	KELAGINAMANE HIRIYANNA	1633
The MAILING DATE of this communication ap Period for Reply	ppears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO .136(a). In no event, however, may a reply be tid d will apply and will expire SIX (6) MONTHS fron the, cause the application to become ABANDONI	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on <u>04 /</u> 2a) This action is FINAL . 2b) Th 3) Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pr	
Disposition of Claims		
4) Claim(s) 1-27 is/are pending in the applicatio 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-27 are subject to restriction and/or	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	ccepted or b) objected to by the e drawing(s) be held in abeyance. Se ction is required if the drawing(s) is ob	ee 37 CFR 1.85(a). pjected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Bures * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat ority documents have been receiv au (PCT Rule 17.2(a)).	tion No red in this National Stage
Attachment(s)	4) 🖂 Intention Com-	v(PTO 413)
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	4)	Oate

Art Unit: 1633

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

The inventions as claimed are classified into following groups:

- I. Claims 1-6 drawn to a transgenic insect or a cell wherein the level of expression of dhr96 or a homologue thereof has been reduced through RNAi.
- II. Claims 1-5 & 7 drawn to a transgenic insect or a cell wherein the level of expression of dhr96 or a homologue thereof has been reduced through insertional mutagenesis.
- III. Claims 1-5 & 8 drawn to a transgenic insect or a cell wherein the level of expression of dhr96 or a homologue thereof has been reduced through homologous recombination.
- IV. Claims 9-12 drawn to a DNA construct encoding dhr96.
- V. Claim13 & 14 drawn to a method of producing a transgenic insect.
- VI. Claim 15 drawn to a method of identifying or verifying the ability of a compound to act as an insecticide.
- VII. Claim 16 drawn to a method of identifying or verifying the ability of a compound to act as a pro-insecticide.
- VIII. Claim 17 drawn to a method of identifying a compound that regulates the expression of dhr96 in cultured cells.
- IX. Claim 18 drawn to a method of identifying a compound that regulates the expression of dhr96 in an insect.
- X. Claims 19-23 drawn to DNA construct encoding the ligand binding domain of DHR96.

Art Unit: 1633

XI. Claims 24, 25 and 27 drawn to a transgenic insect or a transgenic cell comprising DNA construct encoding ligand binding domain of DHR96

XII. Claims 26 drawn to a method of identifying the ability of a compound to act as regulator of DHR96 function.

The inventions listed above as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The inventions listed above as Groups I-XII lack unity of invention because the inventions do not have a common technical feature. For example Claim 1 requires a transgenic insect or a insect cell having a reduced expression of dhr96' whereas claim 16 requires an increased expression of dhr96 and further claim 18 requires the expression of reporter gene under dhr96 promoter'. In addition there is prior art on technical feature of 'a transgenic insect cell with an increased expression dhr96 or a homologue' and hence not make a contribution over the prior art for e.g., of Keith et al (2000, Insect Biochemistry and Molecular Biology 30:1037-1043; teaches a transgenic insect cell expressing dhr96). The invention as whole thus lacks unity under PCT rules and hence a restriction as indicated above is proper. The structure of specific compounds used and/or the distinct phylogeny of insect species used in each of the above inventions and their mode of operation, and the effects evaluated in each of the above invention are distinct and different from the other. Therefore, a search and examination for the patentability of the above inventive groups together would generate an undue search burden on the examiner. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above <u>and</u> there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

Art Unit: 1633

(a) the inventions have acquired a separate status in the art in view of their different classification;

- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
- (d) the prior art applicable to one invention would not likely be applicable to another invention;
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over

the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

This application contains claims directed to the following patentably distinct species: Should Group I, II or III be elected from above, the.

- (a). Applicant is further required to chose a single species of the dhr96 homologue source among the species recited as a Markush group in claim 2.
- (a). Applicant is further required to chose a single species of transgenic insect among the species recited as a Markush group in claim 3.

The species are independent because they are structurally and/or phylogenetically distinct.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be

Art Unit: 1633

traversed. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Kelaginamane Hiriyanna Ph.D., whose telephone number is (571) 272-3307. The examiner can normally be reached Monday through Thursday from 9 AM-7PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach Ph.D., may be reached at (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). When calling please have your application serial number or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. For all other customer support, please call the USPTO call center (UCC) at (800) 786-9199.

/Robert M Kelly/

Primary Examiner, Art Unit 1633